D-4517.2

DRUG2 trials

Sponsors

Ashvattha Therapeutics, Inc.

Conditions

Diabetic Macular EdemaNeovascular Age-related Macular Degeneration

Phase 1

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of D-4517.2 After Subcutaneous Administration in Healthy Participants

CompletedNCT05105607

Ashvattha Therapeutics, Inc.Diabetic Macular Edema, Neovascular Age-related Macular Degeneration

Start: 2022-01-11End: 2022-08-31Updated: 2022-09-21

Phase 2

Safety, Tolerability and PK of Subcutaneous D-4517.2 in Subjects With Wet AMD or DME

Active, not recruitingNCT05387837

Ashvattha Therapeutics, Inc.Diabetic Macular Edema, Neovascular Age-related Macular Degeneration

Start: 2022-08-31End: 2025-09-30Target: 50Updated: 2025-05-04